Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabometyx and Avelumab in mRCC
NCT03200587Phase 1Completed
- Sponsor
- University of Utah
- Start
- Jun 2018
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avelumab and cabozantinib in renal cell carcinoma (RCC), sponsored by University of Utah. Primary endpoints: Recommended Phase 2 Dose and Safety and Tolerability. Started Jun 2018; status: completed.
02
Drugs
avelumabcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03200587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200587.